PubMed Health⌕ Search

Biomedical subjects

E Muls

Publications and source records attributed to E Muls.

At least 19 recordsLinked to original sources
PubMed2003

Predictors of 6-minute walk test results in lean, obese and morbidly obese women.

The aim of this study was first, to assess the presence of medical conditions that might interfere with walking; second, to assess the differences in walking capacity, perceived exertion and physical complaints between lean, obese and morbidly obese women; and third, to identify anthropometric, physical fitness and physical activity variables that contribute to the variability in the distance achieved during a 6-minute walk test in lean and obese women. A total of 85 overweight and obese females (18-65 years, body mass index (BMI) > or = 27.5 kg m(-2)), 133 morbidly obese females (BMI > or = 35 kg m-2) and 82 age-matched sedentary lean female volunteers (BMI < or = 26 kg m(-2)) were recruited. Patients suffering from severe musculoskeletal and cardiopulmonary disease were excluded from the study. Prior to the test, conditions that might interfere with walking and hours of TV watching were asked for. Physical activity pattern was assessed using the Baecke questionnaire. Weight, height, body composition (bioelectrical impedance method), isokinetic concentric quadriceps strength (Cybex) and peak oxygen uptake (peakVO2_bicycle ergometer) were measured. A 6-minute walk test was performed and heart rate, walking distance, Borg rating scale of perceived exertion (RPE) and physical complaints at the end of the test were recorded. In obese and particularly in morbidly obese women suffering from skin friction, urinary stress incontinence, varicose veins, foot static problems and pain, wearing insoles, suffering from knee pain, low back pain or hip arthritis were significantly more prevalent than in lean women (P < 0.05). Morbidly obese women (BMI > 35 kg m(-2)N = 133) walked significantly slower (5.4 km h(-1)) than obese (5.9 km h(-1)) and lean women (7.2 km h(-1), P < 0.05), were more exerted (RPE 13.3, 12.8 and 12.4, respectively, P < 0.05) and complained more frequently of dyspnea (9.1%, 4.7% and 0% resp., P < 0.05) and musculoskeletal pain (34.9%, 17.7% and 11.4% resp., P < 0.05) at the end of the walk. In a multiple regression analysis, 75% of the variance in walking distance could be explained by BMI, peakVO2, quadriceps muscle strength age, and hours TV watching or sports participation. These data suggest that in contrast with lean women, walking ability of obese women is hampered not only by overweight, reduced aerobic capacity and a sedentary life style, but also by perceived discomfort and pain. Advice or programs aimed at increasing walking for exercise also need to address the conditions that interfere with walking, as well as perceived symptoms and walking difficulties in order to improve participation and compliance.

Adolescent↗
PubMed2001

Sequencing of the coding exons of the LRP1 and LDLR genes on individual DNA samples reveals novel mutations in both genes.

Five coding polymorphisms in de LRP1 gene, i.e. A217V, A775P, D2080N, D2632E and G4379S were discovered by sequencing its 89 exons in three test-groups of 22 healthy individuals, 29 Alzheimer patients and 18 individuals with different clinical and molecularly uncharacterized lipid metabolism problems. No genetic defect was evident in the LRP1 gene of any of the Alzheimer's disease (AD) patients, further excluding LRP1 as a major genetic problem in AD. Lipoprotein receptor related protein (LRP) A217V (exon 6) was clearly present in all groups as a polymorphism, while D2632E was observed only once in a healthy volunteer. On the other hand, LRP1 alleles A775P, D2080N, and G4379 were encountered only in patients with FH or with undefined problems of lipid metabolism. This finding forced one to also analyze the LDL receptor (LDLR) gene, for which a method was devised to sequence the entire region comprising LDLR exons 2-18. The resulting sequence contig of 33567 nucleotides yielded finally an exact physical map that corrects published and listed LDLR gene maps in many positions. In addition, next to known mutations in LDLR that cause FH, four novel LDLR defects were defined, i.e. del e7-10, exon 9 mutation N407T, a 20 bp insertion in exon 4, and a double mutation C292W/K290R in exon 6. No evidence for pathology connected to the LRP1 'mutations' was obtained by subsequent screening for the five LRP1 variants in larger groups of 110 FH patients and 118 patients with molecularly undefined, clinical problems of cholesterol and/or lipid metabolism. In three individuals with a mutant LDLR gene a variant LRP1 allele was also present, but without direct, obvious clinical compound effects, indicating that the variant LRP1 alleles must, for the present, be considered polymorphisms.

Adolescent↗
PubMed2001

Exercise capacity in lean versus obese women.

The aim of this study was to assess the nature and magnitude of the differences in submaximal and maximal exercise capacity parameters between lean and obese women. A total of 225 healthy obese women 18-65 years (BMI> or=30 kg/m(2)) and 81 non-athletic lean women (BMI< or=26 kg/m(2)) were selected. Anthropometric measurements (weight and height), body composition assessment (bioelectrical impedance method) and a maximal exercise capacity test on a bicycle ergometer were performed. Oxygen uptake (VO(2)), carbon dioxide production (VCO(2)), expired ventilation (VE), respiratory quotient (RQ), breathing efficiency (VE/VO(2)), mechanical efficiency (ME) and anaerobic threshold (AT) were calculated. At a submaximal intensity load of 70 W, VO(2) (l/min) was larger in the obese women and was already 78% of their peak VO(2), whereas in the non-obese it was only 69% (P=0.0001). VE (l/min) was larger, VE/VO(2) did not differ and ME was lower in obese compared to the lean women. AT occurred at the same percentage of peak VO(2) in both lean and obese women. At peak effort, achieved load, terminal VO(2) (l min(-1) kg(-1)), VE, heart rate, RQ respiratory exchange ratio and perceived exertion were lower in obese subjects compared to the non-obese. Obese subjects mentioned significantly more musculoskeletal pain as a reason to end the test, whereas in lean subjects it was leg fatigue. Lean women recovered better as after 2 min they were already at 35% of the peak VO(2), whereas in the obese women it was 47% (P=0.0001). Our results confirm that exercise capacity is decreased in obesity, both at submaximal and peak intensity, and during recovery. Moreover, at peak effort musculoskeletal pain was an important reason to end the test and not true leg fatigue. These findings are important when designing exercise programs for obese subjects.

Adult↗
PubMed2001

Study of differences in peripheral muscle strength of lean versus obese women: an allometric approach.

OBJECTIVE: To investigate whether peripheral muscle strength is significantly different between lean and obese women controlled for age and physical activity, using an allometric approach. DESIGN: Cross-sectional study of isometric handgrip and isokinetic leg and trunk muscle strength. SUBJECTS: 173 obese (age 39.9+/-11.4 y, body mass index (BMI) 37.8+/-5.3 kg/m(2)) and 80 lean (age 39.7+/-12.2 y, BMI 22.0+/-2.2 kg/m(2)) women. MEASUREMENTS: Anthropometric measures (weight, height) and body composition (bioelectrical impedance method), isometric handgrip (maximal voluntary contraction on the Jamar dynamometer), isokinetic trunk flexion-extension, trunk rotation, and knee flexion-extension (Cybex dynamometers). RESULTS: Absolute isokinetic strength output (that is, strength uncorrected for fat-free mass) was larger in obese compared to lean women, except for knee flexion and isometric handgrip, which were not significantly different (P>0.05). Pearson correlation coefficients between strength measures and fat-free mass (kg) were low to moderate both in lean (r=0.28-0.53, P<0.05) and in obese (r=0.29-0.49, P<0.001) women. There was no correlation with fat mass (kg) in the lean, whereas in the obese women a weak positive relation could be observed for most isokinetic data (r=0.21-0.39, P<0.01). When correcting for fat-free mass (raised to the optimal exponent determined by allometric scaling), all strength measurements were at least 6% lower in obese when compared to the lean women, except for trunk flexion, which was at least 8% stronger in obese women. DISCUSSION: The higher absolute knee extension strength measures of leg and the similar extension strength of the trunk in the obese sample compared to the lean might be explained by the training effect of weight bearing and support of a larger body mass. However when the independent effect of fat-free mass is removed, these strength measures, as well as oblique abdominal muscle and handgrip strength, turned out to be lower in obese women. These observations could be the reflection of the overall impairment of physical fitness as a consequence of obesity and its metabolic complications.

Adult↗
PubMed2001

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.

OBJECTIVE: Assessment of the effects of orlistat 120 mg three times daily vs placebo on weight loss and serum lipids in obese hypercholesterolemic patients. DESIGN: A 24 week multicentre, double-blind, randomized, placebo-controlled trial. After a 2-week single-blind run-in period (placebo+diet (-600 kcal/day; < or =30% of calories as fat)), 294 patients were submitted to the hypocaloric diet and randomly assigned to either orlistat 120 mg or placebo three times daily. Patients who completed the double-blind study (n=255) were eligible for participation in a subsequent 24 week open-label orlistat extension phase. SUBJECTS: Patients with body mass index (BMI) 27-40 kg/m2 and hypercholesterolemia (low-density-lipoprotein cholesterol, LDL-C, 4.1-6.7 mmol/l). MEASUREMENTS: Efficacy assessments included weight loss, lipid levels, other cardiovascular risk factors and anthropometric parameters. Safety assessments. RESULTS: Weight loss during run-in was similar in both groups. After randomization, orlistat-treated patients lost significantly more weight than placebo recipients: mean percentage weight loss from start of run-in to week 24 was-6.8% in the orlistat group and -3.8% in the placebo group (P<0.001). Moreover, more patients in the orlistat group than in the placebo group achieved clinically meaningful weight loss of > or =5% (64 vs 39%) or > or =10% (23 vs 13%) at week 24. Treatment with orlistat was associated with significantly greater changes in total cholesterol (-11.9% vs -4.0%; P<0.001) and LDL-C (-17.6 vs -7.6%; P<0.001). For any category of weight loss during the double-blind treatment period, change in LDL-C was more pronounced in orlistat-treated patients than in placebo recipients, indicating that orlistat had a direct cholesterol-lowering effect that was independent of weight reduction (P<0.001). Adjunction of orlistat during the extension phase in patients who initially received placebo induced a further decrease in weight, total cholesterol and LDL-C. Orlistat was generally well tolerated with a safety profile comparable to placebo, with the exception of a higher incidence of gastrointestinal events (> or =1 event in 64 vs 38% of patients). CONCLUSION: Orlistat as an adjunct to dietary intervention promotes weight loss and reduces LDL-C beyond the effect of weight loss in overweight or obese patients with concomitant hypercholesterolemia.

Adolescent↗
PubMed2001

Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.

Our aim was to determine the usefulness of circulating oxidized low density lipoprotein (LDL) in the identification of patients with coronary artery disease (CAD). A total of 304 subjects were studied: 178 patients with angiographically proven CAD and 126 age-matched subjects without clinical evidence of cardiovascular disease. The Global Risk Assessment Score (GRAS) was calculated on the basis of age, total and high density lipoprotein cholesterol, blood pressure, diabetes mellitus, and smoking. Levels of circulating oxidized LDL were measured in a monoclonal antibody 4E6-based competition ELISA. Compared with control subjects, CAD patients had higher levels of circulating oxidized LDL (P<0.001) and a higher GRAS (P<0.001). The sensitivity for CAD was 76% for circulating oxidized LDL (55% for men and 81% for women) compared with 20% (24% for men and 12% for women) for GRAS, with a specificity of 90%. Logistic regression analysis revealed that the predictive value of oxidized LDL was additive to that of GRAS (P<0.001). Ninety-four percent of the subjects with high (exceeding the 90th percentile of distribution in control subjects) circulating oxidized LDL and high GRAS had CAD (94% of the men and 100% of the women). Thus, circulating oxidized LDL is a sensitive marker of CAD. Addition of oxidized LDL to the established risk factors may improve cardiovascular risk prediction.

Aged↗
PubMed2001

The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial.

OBJECTIVE: LIPI-GOAL is a multicentre, open-label, non-comparative treat-to-target study, conducted from March 1998 to May 1999, that assessed the percentage of patients reaching 1992 European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) targets with atorvastatin 10-80 mg/day in subjects with hypercholesterolaemia, defined as LDL-C > 160 mg/dl after a 12-week step I diet. METHODS AND RESULTS: Patients were treated towards the following LDL-C goals: < 135 mg/dl in patients with atherosclerotic disease present and/or coronary heart disease (CHD) risk >40%/10 years, or LDL-C < 155 mg/dl in all others. All subjects started treatment with atorvastatin 10 mg/day for 6 weeks. The dose was doubled every 6 weeks, to 20, 40, or 80 mg/day at weeks 12, 18, and 24, respectively, if targets were not reached. Of 587 patients screened for participation, 473 were enrolled and 419 (59% male; mean age 61 years) were available for efficacy evaluation. Fifty-five percent had atherosclerotic disease and/or CHD risk >40%/10 years. Dose titration was not needed in 303 patients (72%) who reached LDL-C target with atorvastatin 10 mg/day. Among 116 patients who were subsequently treated with higher atorvastatin dosages, 47 reached LDL-C target with 20 mg/day, 15 with 40 mg/day, and 6 with 80 mg/day. Therefore, 88.5% of subjects reached LDL-C goal in an intention-to-treat analysis. In general, atorvastatin was well tolerated. CONCLUSIONS: Most patients at high risk for CHD reached LDL-C goals with atorvastatin 10-80 mg/day. Seventy-two % of patients reached target with atorvastatin 10 mg/day, which may simplify clinical management and should encourage better adherence to recommendations.

Aged↗
PubMed2001

The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.

OBJECTIVE: To determine the effect of atorvastatin on postprandial lipaemia in overweight or obese women with the apoprotein (apo) E3/E3 genotype. DESIGN: Double-blind randomised, placebo-controlled 8-week single-centre study. SUBJECTS: Twenty-two healthy women, homozygous for apo E3 with a BMI ranging from 27.6 to 41.1 kg/m2 and normal or moderately elevated fasting triglycerides (53-184 mg/dl). TREATMENT: After a 4-week isocaloric single-blind, placebo lead-in period, subjects were randomly assigned to receive either placebo (n = 7) or atorvastatin 20 mg once daily in the evening (n = 15) for 4 weeks. RESULTS: Atorvastatin significantly reduces fasting total cholesterol, LDL-cholesterol and postprandial triglycerides in obese women, homozygous for apo E3 with normal or near-normal fasting triglyceride levels. No significant effect on fasting triglycerides was observed. CONCLUSION: Atorvastatin decreases postprandial hyperlipidaemia, an independent cardiovascular risk factor, in normolipidaemic obese women. This effect of atorvastatin may, therefore, represent a cardioprotective mechanism.

Adult↗
PubMed2001

Corneal opacifications in a low high density lipoprotein syndrome: suspicion of fish eye disease: a case report.

A 49 year old patient with progressive massive bilateral corneal opacifications associated with a HDL (high-density-lipoprotein) deficiency is described. The opacifications started at the age of twenty and progressed slowly. They were found diffusely over the cornea, though more in the corneal periphery. A penetrating keratoplasty at the right eye was performed. The diagnosis of Fish Eye Disease was put forward on the basis of the ophthalmological, clinical, biochemical and pathological appearance. After 2 year follow-up, the graft was clear. The final distance and near vision of the right eye was 8/10 and Snellen 1 respectively.

Adult↗
PubMed1999

Effect of exercise training on long-term weight maintenance in weight-reduced men.

This study investigated whether endurance training is effective for successful long-term weight maintenance after weight reduction. Fifteen male obese subjects (age, 37.3+/-5.2 years; body weight [BW], 96.2+/-13.6 kg; body mass index [BMI], 30.9+/-2.8 kg x m(-2)) participated in a 16-month exercise-intervention study. During the first 4 months, all subjects trained three to four times weekly, consuming a very-low-energy diet (VLED) during the first 2 months. After the 4-month treatment period, seven subjects continued training for 12 months (3 to 4 times per week). The other eight subjects served as a control group not involved in a training program. The regain (increase during the intervention period as a percentage of the 4-month treatment) of BW at 16 months was 64% (+/-26%) for the whole group (trained v. control, 52%+/-28% v. 74%+/-20%, P = .09). The increase in absolute fat mass (FM) was significantly lower at 16 months for the trained group (trained v. control, 4.8+/-1.9 v. 9.0+/-3.3 kg), as was the regain of FM at 16 months (trained v. control, 61%+/-24% v. 92%+/-32%, P = .05). The amount of regain of the waist circumference, waist to hip ratio (WHR), and sagittal diameter were correlated with the amount of training (hours) performed weekly (deltawaist, r = -.55, P<.05; deltaWHR, r = -.50, P = .06; deltasagittal diameter, r = -.53, P<.05). Physical fitness parameters (maximal power output [Wmax] and oxygen uptake [Vo2 max]) were significantly increased in both groups at 4 months. Trained subjects maintained high levels of physical fitness at 16 months, in contrast to the control group. In conclusion, although BW regain was not significantly different between the groups, trained subjects showed less regain of FM and higher levels of physical fitness, factors related to a lower risk for cardiovascular disease (CVD), compared with the control group. Furthermore, the regain of FM, which occurred even in the exercising group with a relatively intensive training program, suggests that maintenance of fat loss is extremely difficult.

Adipose Tissue↗
PubMed1999

Determinants of postprandial lipemia in obese women.

OBJECTIVE: To quantify the effects of fasting lipids, age, apolipoprotein (apo) E polymorphism, insulin resistance, body fat and abdominal fat distribution, on postprandial lipemia (PPL) in non-diabetic obese women. DESIGN: Cross-sectional, prospective. SUBJECTS: A total of 93 obese women (mean +/- s.d. age 39+/-13y; body mass index (BMI) 38.3+/-4.9 kg/m2) and 16 nonobese women (25+/-8y; BMI 22.7+/-3.2 kg/m2). MEASUREMENTS: Body fat distribution was determined by the ratio of waist-to-hip circumferences (WHR) and by computed tomography (CT) at the L4-L5 level. Apo E genotyping was performed by restriction isotyping. Insulin resistance was calculated from fasting glucose and insulin concentrations. PPL was evaluated using the vitamin A-fat tolerance test (1.0 g fat/kg body weight and 7.0 mg cholesterol/kg body weight+300000 IU vitamin A palmitate). Blood samples were drawn before, and every 1.5 h for 7.5 h plus 24 h after ingestion of the fat meal. Areas under the response curves (AUC) for triglycerides (TG) and retinyl palmitate (RP) were calculated using the geometrical method for two time intervals, that is, 0-7.5 h and 0-24 h. RESULTS: Incremental AUCs TG, but not AUCs RP, were increased in the obese women. Apo E polymorphism, BMI, WHR and menopausal state did not influence PPL in the obese women. Fasting TG, age, the intra-abdominal to subcutaneous abdominal fat ratio (IA/SC ratio) and insulin resistance were independent determinants of PPL. Together, fasting TG, IA/SC ratio and insulin resistance, explained 38% of the variance in AUC TG 0-7.5 h (P = 0.0001). CONCLUSION: Alterations in PPL are to be added to the increasing number of components of the plurimetabolic syndrome.

Adolescent↗
PubMed1999

A multidisciplinary approach to the treatment of obesity.

OBJECTIVE: The aim of this paper is: (1) To describe a long-term multidisciplinary group approach to the treatment of morbidly obese persons; and (2) to present, in a preliminary report, results at three months in 30 obese women. DESIGN: Prospective study with evaluation at the start of therapy and after three months of therapy. SUBJECTS: Thirty obese women, initial mean BMI 35.3 kg/m2, age 28-67 y. RESULTS: Body weight decreased significantly (-6 kg) with 74% of weight loss as fat mass. This moderate decrease in body weight resulted in a significant improvement of VO2max/kg body weight. Resting metabolic rate and metabolic parameters remained unchanged. Among psychological variables, participating in the therapy resulted in a more pronounced restrained eating behaviour, an improvement of body image and a higher expression of positive feelings and actions. CONCLUSION: Preliminary results of the program are encouraging. However, continuous evaluation and improvement of the program in the long-term (at least several years) are extremely important.

Adult↗
PubMed1999

New directions in public health approach to obesity management.

Increasing recognition of the world-wide obesity epidemic as a major public health problem has recently led to new directions in the public health approach of the management of obesity, including new public health strategies, and appropriate programs for the obese individual.

Adult↗
PubMed1999

Clinical approaches to healthier diet modifications.

There is a strong relation between diet and risk factors for cardiovascular diseases. Generally a high fat consumption will increase the serum cholesterol level. Different fatty acids have different effects on total cholesterol, LDL and HDL lipoproteins and therefore on the risk for cardiovascular diseases. This knowledge was translated into guidelines for a healthy diet and in advices to use less fat. In reality it was not easy for physicians to reach a substantial reduction in total cholesterol by limiting the fat consumption. A recent investigation in Belgium showed that the median reduction obtained by dietary changes through general practitioners was only 3.5%. In medical education not much attention is paid to the communication of the "fat message". In addition, individual patients have frequently multiple risk factors e.g. abdominal obesity, insulin resistance, diabetes, hypertension and a sedentary lifestyle. Therefore in the clinical setting an integrated approach is needed, in which dietary advice is supported by behavioural therapy and suggestions to increase physical activity. Currently there is a debate on the preference of a low fat or a modified fat diet. A low fat diet is rich in carbohydrates and a modified fat diet is rich in mono-unsaturated fatty acids. Recent investigations in diabetic patients are in favour of a modified fat diet. This has the advantage that in practice the possibilities for realizing a low saturated fat diet are increased.

Cardiovascular Diseases↗
PubMed1998

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.

Methodological differences and variations in health care regulations among countries often preclude direct comparisons of cost-effectiveness studies. A projected risk model was applied, designed to determine the economic value in the United States of pravastatin in the secondary prevention of coronary heart disease (CHD), to Belgium using local health care costs. A Markov process was used to model the effectiveness of treatment for 3 years with pravastatin versus placebo in 1000 male CHD patients aged 60 years and clinically similar to those in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) and pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II) studies. The PLAC I and II trials have shown that pravastatin treatment for 3 years at a weighted mean dose of 36.64 mg daily significantly reduced the incidence of non-fatal myocardial infarction in patients with CHD. Framingham data were used to project the risk of mortality 10 years post-myocardial infarction. The incremental cost per life year gained (LYG), after discounting costs and benefits by 5% annually, in the setting of Belgian health care regulations, was Belgian francs (BEF) 720794 (US$ 24359) for CHD patients with one additional risk factor; BEF 526464 (US$ 17792) for those with two additional risk factors; and BEF 392765 (US$ 13274) for those with three or more additional risk factors. The cost per LYG in Belgium appeared to be more sensitive to drug acquisition cost than to costs of medical interventions. The cost-effectiveness ratios of pravastatin monotherapy for 3 years in secondary prevention of CHD, obtained with the same projected risk model, are from 86 to 92% higher in Belgium than in the United States, due to differences in medical patterns of practice and in intervention costs.

Anticholesteremic Agents↗
PubMed1997

Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.

OBJECTIVE: To assess the effects of BMI at baseline and on-treatment weight change on the lipid-lowering efficacy of diet plus fibric acid derivatives (fibrates) in hypercholesterolemic adults. SUBJECTS: 6003 participants in a Belgian General Practitioners Trial, an open-label, prospective study conducted in a primary care setting. MEASURES: Effect of initial BMI, on-treatment weight change, or lipid values at baseline on percentage changes in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Multiple linear regression models, including initial BMI, on-treatment weight change, age, gender, and baseline lipid values, were fitted to control the influences exerted by these variables on each other. RESULTS: Reductions in LDL-C after diet plus fibrate treatment for 12 weeks were inversely related to initial BMI and to TG levels at baseline, and were positively associated with baseline LDL-C concentrations and with on-treatment weight change (P < 0.001 for all analyses). Decreases in TG related negatively with initial BMI (P = 0.012), and positively with weight loss (P = 0.011) and TG at baseline (P < 0.001). Increases in HDL-C were negatively associated with initial BMI (P = 0.012) and with baseline TG (P < 0.001). CONCLUSIONS: The LDL-C lowering efficacy of fibrates is inversely related to initial BMI, and is positively associated with on-treatment weight loss.

Body Mass Index↗